2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. DGK

DGK

Diacylglycerol kinase;

DGK (Diacylglycerol Kinase) modulates the balance between DAG and phosphatidic acid (PA). DGK phorylates DAG to generate PA. DGK has ten mammalian DGK subtypes (α-κ) with subtype-specific tissue distribution, and they can be classified into 5 types. Among them, DGKα and DGKζ specifically regulate the pool of DAG that is generated as a second messenger after stimulation of the T cell receptor. Whereas, DGKζ is the dominant isoform in T cells. Dysregulation of certain DGK isoforms leads to DAG-activation of PKC, attenuation of insulin signaling, and dysregulation of glucose metabolism. DGK plays a role in many physiological events, including cell proliferation and migration, glucose intake, immunity and neuronal network construction[1][2][3].

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-121638
    CU-3
    		Inhibitor
    CU-3 is a DGKα inhibitor with an IC50 of 0.6 μM. CU-3 competitively reduces DGKα’s affinity for ATP via binding to the enzyme’s catalytic region. CU-3 induces apoptosis in cancer cells. CU-3 promotes T-cell activation and enhances IL-2 production. CU-3 can be used for the research of hepatocellular carcinoma and cervical cancer.
    CU-3
  • HY-177601
    DGK-IN-11
    		Inhibitor
    DGK-IN-11 (Compound 1) is a diacylglycerol kinase (DGK) inhibitor. DGK-IN-11 exhibits inhibitory activity against DGKα and DGKγ. DGK-IN-11 regulates intracellular diacylglycerol levels and enhances T cell activation, cytokine production, and proliferation. DGK-IN-11 can be used for the study of cancer.
    DGK-IN-11
  • HY-178062
    DGKα-IN-10
    		Inhibitor
    DGKα-IN-10 is an orally active and potent DGKα inhibitor with an IC50 of 0.27 nM. DGKα-IN-10 can induce IL-2 release and T cells proliferation. DGKα-IN-10 can be used for the research of cancer, such as colon cancer.
    DGKα-IN-10
  • HY-156578
    DGKα-IN-8
    		Inhibitor
    DGKα-IN-8 (Example 51) is a DGKα inhibitor (IC50=22.491 nM; EC50=0.256 nM). DGKα-IN-8 can be used to study cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection.
    DGKα-IN-8
  • HY-175727
    DGKα-IN-9
    		Inhibitor
    DGKα-IN-9 is a diacylglycerol kinase alpha (DGKα) inhibitor. DGKα-IN-9 demonstrates a tumor growth inhibition in MC38 or or CT26 mouse tumor model. DGKα-IN-9 can be used for the study of cancer.
    DGKα-IN-9
  • HY-164905
    DGK-IN-8
    		Inhibitor
    DGK-IN-8 (Example 34) is a DGK inhibitor, with IC50 of ≤ 20 nM for DGKα and ζ. DGK-IN-8 can be used for cancer research.
    DGK-IN-8
  • HY-156571
    DGKα-IN-4
    		Inhibitor
    DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC50 of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.
    DGKα-IN-4
  • HY-156572
    DGKζ-IN-3
    		Inhibitor
    DGKζ-IN-3 is a DGK-zeta-inhibitor. DGKζ-IN-3 is used in liquid and solid cancer and other diacylglycerol kinase zeta (DGK-ζ) regulation of diseases.
    DGKζ-IN-3
  • HY-170427
    DGKζ-IN-10
    		Inhibitor
    DGKζ-IN-10 (compound 349) is a DGKζ inhibitor, with an IC50 ≤200 nM.
    DGKζ-IN-10
  • HY-156570
    DGKα-IN-3
    		Inhibitor
    DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-3
  • HY-178327
    DGKα&ζ-IN-2
    		Inhibitor
    DGKα/ζ-IN-2 is a potent, orally active and selective dual DGKα/ζ inhibitor with IC50 values of 23 nM (DGKα) and 1.2 nM (DGKζ). DGKα/ζ-IN-2 exhibits selectivity over other DGK isoforms, such as DGKβ and DGKγ. DGKα/ζ-IN-2 shows robust and dose-dependent immune activation in the presence of antigen presentation in an OT-1 murine model. DGKα/ζ-IN-2 can be used for antitumor immunity.
    DGKα&ζ-IN-2
  • HY-169318
    DGKζ-IN-7
    		Inhibitor
    DGKζ-IN-7 (compound 97) is an oral active DGKζ inhibitor with the IC50 of 33.4 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases.
    DGKζ-IN-7
  • HY-160123
    DGKζ-IN-5
    		Inhibitor
    DGKζ-IN-5 is a DGKζ inhibitor (WO2023125681A1; compound A27a).
    DGKζ-IN-5
  • HY-156576
    DGKα-IN-6
    		Inhibitor
    DGKα-IN-6 is a DGKα inhibitor with the IC50 of 1.377 nM, extracted from patent WO2022271650 (compound 143). DGKα-IN-6 has the potential for cancer study.
    DGKα-IN-6
  • HY-177603
    DGK-IN-13
    		Inhibitor
    DGK-IN-13 is a DGK inhibitor. DGK-IN-13 can be used for the research of cancer.
    DGK-IN-13
  • HY-126599
    Cochlioquinone A
    		Inhibitor
    Cochlioquinone A is a ATP-competive diacylglycerol kinase inhibitor (Ki: 3.1 μM). Cochlioquinone A can be isolated from Drechslera sacchari.
    Cochlioquinone A
  • HY-156573
    DGKα/ζ-IN-1
    		Inhibitor
    DGKα/ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα/ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor.
    DGKα/ζ-IN-1
  • HY-177602
    DGK-IN-12
    		Inhibitor
    DGK-IN-12 is a DGK inhibitor. DGK-IN-12 can be used for the research of cancer.
    DGK-IN-12
  • HY-170426
    DGKζ-IN-9
    		Inhibitor
    DGKζ-IN-9 (compound 73) is a DGKζ inhibitor, with an IC50 ≤200 nM.
    DGKζ-IN-9
  • HY-D3314
    1-NBD-Stearoyl-2-arachidonoyl-sn-glycerol
    		Substrate
    1-NBD-Stearoyl-2-arachidonoyl-sn-glycerol (NBD-SAG) is a fluorescently labeled 1-Stearoyl-2-arachidonoyl-sn-glycerol (HY-131897). 1-NBD-Stearoyl-2-arachidonoyl-sn-glycerol acts as a fluorescent probe for the measurement of DGKε enzymatic activity.
    1-NBD-Stearoyl-2-arachidonoyl-sn-glycerol
Cat. No. Product Name / Synonyms Application Reactivity